Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vitro characterization of a novel Ca2+ entry blocker: SR 33805

P Chatelain1, M Clinet, P Polster

  • 1Sanofi-Pharma Research Centre 1, Brussels, Belgium.

European Journal of Pharmacology
|August 15, 1993
PubMed
Summary

SR 33805 is a potent calcium channel antagonist that selectively targets vascular smooth muscle. Unlike other agents, it lacks significant negative inotropic actions, making it a promising therapeutic candidate.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovering Salient Anatomical Landmarks by Predicting Human Gaze.

Proceedings. IEEE International Symposium on Biomedical Imaging·2020
Same author

Spatio-Temporal Partitioning and Description of Full-Length Routine Fetal Anomaly Ultrasound Scans.

Proceedings. IEEE International Symposium on Biomedical Imaging·2020
Same author

Expected-value bias in routine third-trimester growth scans.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2019
Same author

SonoEyeNet: Standardized Fetal Ultrasound Plane Detection Informed by Eye Tracking.

Proceedings. IEEE International Symposium on Biomedical Imaging·2019
Same author

Detection of carbapenemase activity in Pseudomonas aeruginosa by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS).

Journal of microbiological methods·2018
Same author

[Economic impact of etanercept and adalimumab biosimilars on hospitals scale covered by PharmAlp'Ain, a hospitals grouping of orders for health products].

Annales pharmaceutiques francaises·2017

Area of Science:

  • Pharmacology
  • Cardiovascular Research
  • Smooth Muscle Physiology

Background:

  • Calcium channel blockers are crucial for managing cardiovascular diseases.
  • Understanding the selectivity and potency of novel calcium channel antagonists is essential for drug development.

Purpose of the Study:

  • To characterize the pharmacological profile of SR 33805 as a calcium channel antagonist.
  • To compare the efficacy and selectivity of SR 33805 against established calcium channel blockers.

Main Methods:

  • Competitive and allosteric binding assays to cardiac sarcolemmal membranes.
  • Assessment of negative chronotropic and inotropic effects in isolated rabbit atria.
  • Evaluation of inhibition of 45Ca2+ influx and contractile responses in rat aortic strips.

Related Experiment Videos

  • Antagonism of K(+)-induced and Ca(2+)-induced contractions in various arterial preparations.

    • Main Results:

    • SR 33805 competitively inhibited [3H]fantofarone binding and allosterically inhibited other calcium channel ligand binding.
    • It demonstrated lower potency in negative chronotropic and inotropic responses compared to fantofarone, nifedipine, verapamil, and diltiazem.
    • SR 33805 significantly inhibited K(+)-induced 45Ca2+ influx and contractions in rat aortic strips, with a pA2 value of 8.39 +/- 0.02.
    • In femoral, renal, and basilar arteries, SR 33805 was equipotent to other antagonists for K(+)-induced contractions but less potent for serotonin-induced contractions, suggesting membrane potential-dependent effects.

    Conclusions:

    • SR 33805 is a potent calcium channel antagonist.
    • It exhibits high selectivity for vascular smooth muscle.
    • SR 33805 is devoid of potent negative inotropic actions, differentiating it from fantofarone, verapamil, and diltiazem.